BriSTAR Immunotech, a clinical-stage cell therapy company based in Beijing, has received tacit clinical trial approval from the Center for Drug Evaluation (CDE) in China for its YTS104, a specific LILRB4-targeted cell therapy based on its STAR-T platform. The targeted indications for YTS104 include recurrent/refractory acute myeloid leukemia (AML), chronic myelomonocytic leukemia (CMML), and others.
YTS104, an autologous cell therapy co-developed with Tsinghua University, has demonstrated positive data in early studies, effectively eliminating target-positive tumor cells. The drug was granted Orphan Drug Designation (ODD) status in the US in December 2022.
The target of YTS104, LILRB4 (also known as ILT3, CD85k), is a myeloid immunosuppressive receptor that is highly expressed on monocyte AML mother cells (FAB M4 and M5 AML subtypes), making it an ideal therapeutic target for monocyte AML.- Flcube.com
